학술논문
Preventive treatment of migraine: Non-specific oral agents.
Document Type
Academic Journal
Author
Tronvik E; Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; NorHEAD - Norwegian Center for Headache Research, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Department of Neurology, St Olavs University Hospital, Trondheim, Norway. Electronic address: erling.tronvik@ntnu.no.; Giri S; Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; NorHEAD - Norwegian Center for Headache Research, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.; Young W; Department of Neurology, Thomas Jefferson University, Philadelphia, PA, United States.
Source
Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0166161 Publication Model: Print Cited Medium: Internet ISSN: 0072-9752 (Print) Linking ISSN: 00729752 NLM ISO Abbreviation: Handb Clin Neurol Subsets: MEDLINE
Subject
Language
English
ISSN
0072-9752
Abstract
Migraine headache is highly prevalent and the most common neurologic disorder, affecting one billion people worldwide. It is also the most disabling condition in people under 50, with a huge impact on working ability, family, and social life. Access to effective preventive medication is important and may be considered if the patient has 6 or more migraine days per month, ineffective abortive agents, or disability on 2 or more days per month. Propranolol, metoprolol, candesartan, topiramate, divalproex, lisinopril, amitriptyline, and venlafaxine have the strongest evidence to support for use. Flunarizine and pizotifen may also be effective. Selection of preventive treatments is based on individual characteristics, comorbid conditions, efficacy, contraindications, side effects, cost, compliance, and drug. An adequate trial of migraine prophylaxis is usually 2 months at the target dose, and it is always important to re-evaluate indication for prophylactic use after a period of time.
(Copyright © 2024 Elsevier B.V. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
(Copyright © 2024 Elsevier B.V. All rights reserved, including those for text and data mining, AI training, and similar technologies.)